NLS Pharmaceutics Schedules Shareholder Meeting for Jan 14
Ticker: NCEL · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
Related Tickers: NLS
TL;DR
NLS Pharma calling a shareholder meeting Jan 14, 2025. Record date Dec 23, 2024. Vote matters!
AI Summary
NLS Pharmaceutics Ltd. has scheduled an Extraordinary Shareholders' Meeting for January 14, 2025. Shareholders of record as of December 23, 2024, will be eligible to vote on matters presented at the meeting. The filing includes the Notice of Meeting and Proxy Card.
Why It Matters
This meeting is a crucial step for NLS Pharmaceutics to potentially make significant corporate decisions that could impact its future direction and shareholder value.
Risk Assessment
Risk Level: low — This filing is a routine notice of a shareholder meeting and does not contain new financial or operational risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- January 14, 2025 (date) — Extraordinary Shareholders' Meeting date
- December 23, 2024 (date) — Record date for shareholders eligible to vote
FAQ
What is the purpose of the Extraordinary Shareholders' Meeting?
The purpose is to present matters for shareholders to vote on, as detailed in the Notice of Meeting and Proxy Card.
Who is eligible to vote at the meeting?
Shareholders of record who hold common and/or preferred shares of NLS Pharmaceutics Ltd. at the close of business on December 23, 2024 (11:59 pm CET) are eligible to vote.
When will the Extraordinary Shareholders' Meeting be held?
The meeting is scheduled to be held on January 14, 2025.
What documents are included with this 6-K filing?
The filing includes the Notice of Meeting and Proxy Card for the Extraordinary Shareholders' Meeting.
What is the company's principal executive office address?
The company's principal executive office is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 310 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-12-23 16:04:53
Filing Documents
- ea0225558-6k_nlspharma.htm (6-K) — 12KB
- ea022555801ex99-1_nlspharma.htm (EX-99.1) — 81KB
- ex99-1_001.jpg (GRAPHIC) — 705KB
- ex99-1_002.jpg (GRAPHIC) — 1265KB
- 0001213900-24-111884.txt ( ) — 2807KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 23, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 3